Jane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Jane Street Group LLC trimmed its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 86.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 204,750 shares of the company’s stock after selling 1,345,226 shares during the quarter. Jane Street Group LLC owned 0.16% of Karyopharm Therapeutics worth $170,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of KPTI. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $143,000. Acadian Asset Management LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $167,000. Exchange Traded Concepts LLC raised its position in shares of Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the period. Finally, FMR LLC raised its position in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares during the period. 66.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $0.67 on Tuesday. The company has a market capitalization of $84.90 million, a PE ratio of -0.59 and a beta of 0.07. The business has a fifty day moving average price of $0.77 and a two-hundred day moving average price of $0.81. Karyopharm Therapeutics Inc. has a 1 year low of $0.58 and a 1 year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the company earned ($0.30) EPS. Sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -0.94 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).